Retour

Bausch + Lomb Corporation

Qualité des données : 100%

BLCO

NYSE Healthcare Medical - Instruments & Supplies

16,02 €

▲ 0,31 € (1,97%)

Cap. Boursière : 5,68B

Fourchette du Jour

15,76 € 16,15 €

Fourchette 52 Semaines

10,45 € 18,92 €

Volume

335 085

Moyenne 50J / 200J

17,19 € / 15,41 €

Clôture Précédente

15,71 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (631 pairs)

Métrique	Action	Médiane du Secteur
P/E	-15,8	0,2
P/B	0,9	3,0
ROE %	-5,6	3,6
Net Margin %	-7,1	3,8
Rev Growth 5Y %	7,9	10,0
D/E	0,8	0,2

Objectif de Cours des Analystes

Hold

18,90 € +18.0%

Low: 16,00 € High: 21,00 €

P/E Prévisionnel

20,70

BPA Prévisionnel

0,77 €

Croissance BPA (est.)

+0,0%

CA Est.

5,43B

Estimations de Bénéfices

Période	BPA Est.	CA Est.	Analystes
FY2029	1,78 € 1,76 € – 1,79 €	5,93B	1
FY2028	1,35 € 1,04 € – 1,58 €	6,06B	3
FY2027	1,05 € 0,94 € – 1,26 €	5,74B	8

Earnings Surprises

Last 8 quarters

Quarter	Est. EPS	Actual EPS	Surprise
2026-02-18	0,36 €	0,32 €	-9,9%
2025-10-29	0,16 €	0,18 €	+12,5%
2025-07-30	0,06 €	0,07 €	+16,7%
2025-04-30	0,03 €	-0,07 €	-333,3%
2025-02-19	0,24 €	0,25 €	+4,2%
2024-10-30	0,16 €	0,17 €	+6,3%
2024-07-31	0,13 €	0,13 €	0,0%
2024-05-01	0,09 €	0,07 €	-22,2%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue grew 7,89% annually over 5 years — modest growth

Negative free cash flow of -66,00M

Capital efficient — spends only 6,84% of revenue on capex

ROIC of 1,01% — low return on invested capital

Interest coverage of 0,37× — tight debt servicing

Croissance

Revenue Growth (5Y)

7,89%

Revenue (1Y)6,47%

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Qualité

Return on Equity

-5,57%

ROIC1,01%

Net Margin-7,06%

Op. Margin3,12%

Sécurité

Debt / Equity

0,83

Current Ratio1,55

Interest Coverage0,37

Valorisation

P/E Ratio

-15,77

Forward P/E20,70

P/B Ratio0,88

EV/EBITDA67,06

Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	6,47%	Revenue Growth (3Y)	10,92%
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	7,89%	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	5,10B	Net Income (TTM)	-360,00M
ROE	-5,57%	ROA	-2,57%
Gross Margin	58,71%	Operating Margin	3,12%
Net Margin	-7,06%	Free Cash Flow (TTM)	-66,00M
ROIC	1,01%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0,83	Current Ratio	1,55
Interest Coverage	0,37
Dividends
Dividend Yield	0,00%	Payout Ratio	0,00%
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-15,77	Forward P/E	20,70
P/B Ratio	0,88	P/S Ratio	1,11
PEG Ratio	-1,26	Forward PEG	N/A
EV/EBITDA	67,06	Fwd EV/EBITDA	13,80
Forward P/S	1,04	Fwd Earnings Yield	4,83%
FCF Yield	-1,16%
Market Cap	5,68B	Enterprise Value	10,66B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	5,10B	4,79B	4,15B	3,77B	3,77B
Net Income	-360,00M	-317,00M	-260,00M	6,00M	182,00M
EPS (Diluted)	-1,02	-0,90	-0,74	0,04	0,52
Gross Profit	3,00B	2,92B	2,50B	2,25B	2,30B
Operating Income	159,00M	162,00M	130,00M	207,00M	329,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	14,02B	13,47B	13,44B	11,14B	10,82B
Total Liabilities	7,50B	6,93B	6,52B	4,04B	1,42B
Shareholders' Equity	6,45B	6,47B	6,85B	7,03B	9,33B
Total Debt	5,37B	4,94B	4,68B	2,55B	140,00M
Cash & Equivalents	383,00M	305,00M	334,00M	380,00M	174,00M
Current Assets	2,98B	2,79B	2,74B	2,14B	1,64B
Current Liabilities	1,92B	1,74B	1,58B	1,30B	1,10B